Cargando…

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma

Multiple myeloma (MM) and its precursors monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) are 2–3 times more common in African Americans (AA) than European Americans (EA). Although epigenetic changes are well recognized in the context of myeloma cell biology, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiu, Brian C.-H., Zhang, Zhou, Derman, Benjamin A., Karpus, Jason, Luo, Liangzhi, Zhang, Sheng, Langerman, Spencer S., Sukhanova, Madina, Bhatti, Parveen, Jakubowiak, Andrzej, He, Chuan, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380317/ https://www.ncbi.nlm.nih.gov/pubmed/35974364 http://dx.doi.org/10.1186/s13045-022-01327-y

Ejemplares similares

Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis
por: Derman, Benjamin A., et al.
Publicado: (2020)

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Wang, Bei, et al.
Publicado: (2022)

Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2022)

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
por: Derman, Benjamin A., et al.
Publicado: (2021)

5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype
por: Applebaum, Mark A., et al.
Publicado: (2019)

Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia
por: Shao, Jianming, et al.
Publicado: (2022)

An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas
por: Cai, Jiajun, et al.
Publicado: (2021)

Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma
por: Cai, Jiabin, et al.
Publicado: (2019)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers
por: Li, Wenshuai, et al.
Publicado: (2017)

5-Hydroxymethylcytosines in circulating cell-free DNA reveal a diagnostic biomarker for glioma
por: Zhang, Chunyu, et al.
Publicado: (2022)

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Early Warning Biomarkers for COVID-19 Progression and Myocardial Injury
por: Chen, Hang-yu, et al.
Publicado: (2022)

5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic and predictive biomarkers for coronary artery disease
por: Dong, Chaoran, et al.
Publicado: (2020)

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2023)

Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study
por: Derman, Benjamin A, et al.
Publicado: (2020)

Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine
por: Shao, Jianming, et al.
Publicado: (2023)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA
por: Guler, Gulfem D., et al.
Publicado: (2020)

Genome-wide hydroxymethylcytosine pattern changes in response to oxidative stress
por: Delatte, Benjamin, et al.
Publicado: (2015)

Genome-Wide Alteration of 5-Hydroxymethylcytosine in Hypoxic-Ischemic Neonatal Rat Model of Cerebral Palsy
por: Zhang, Yunpeng, et al.
Publicado: (2019)

Genome-wide profiling of DNA 5-hydroxymethylcytosine during rat Sertoli cell maturation
por: Landfors, Miriam, et al.
Publicado: (2017)

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma
por: Willrich, Maria Alice V., et al.
Publicado: (2022)

A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation
por: Cui, Xiao-Long, et al.
Publicado: (2020)

Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia
por: Shao, Jianming, et al.
Publicado: (2023)

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2023)

Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
por: Qiang, Wanting, et al.
Publicado: (2023)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma
por: Spencer, Andrew, et al.
Publicado: (2019)

A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma
por: Kim, Si-Cho, et al.
Publicado: (2023)

Genome-wide 5-hydroxymethylcytosine patterns in human spermatogenesis are associated with semen quality
por: Efimova, Olga A., et al.
Publicado: (2017)

Comprehensive evaluation of genome-wide 5-hydroxymethylcytosine profiling approaches in human DNA
por: Skvortsova, Ksenia, et al.
Publicado: (2017)

Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma
por: Claveau, Jean-Sébastien, et al.
Publicado: (2022)

Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy
por: Zeng, Chang, et al.
Publicado: (2019)

5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages
por: Song, Chun-Xiao, et al.
Publicado: (2017)

PETCH-DB: a Portal for Exploring Tissue-specific and Complex disease-associated 5-Hydroxymethylcytosines
por: Cai, Qinyun, et al.
Publicado: (2023)

Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma
por: Xia, Yuan, et al.
Publicado: (2022)

5‐Hydroxymethylcytosine signature in circulating cell‐free DNA as a potential diagnostic factor for early‐stage colorectal cancer and precancerous adenoma
por: Xiao, ZeWen, et al.
Publicado: (2020)

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021)

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
por: Sjöström, Martin, et al.
Publicado: (2022)

Bisulfite-free, single base-resolution analysis of 5-hydroxymethylcytosine in genomic DNA by chemical-mediated mismatch
por: Wang, Yafen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_do8lihcurcn9iu8sa281d9i25h